Microinvasive Nd : YAG laser therapy of early glottic carcinoma and its effect on soluble interleukin-2 receptor, interleukin-2, and natural killer cells

TY - JOUR

T1 - Microinvasive Nd : YAG laser therapy of early glottic carcinoma and its effect on soluble interleukin-2 receptor, interleukin-2, and natural killer cells

AU - Lai, JP

AU - Tao, ZD

AU - Xiao, JY

AU - Chen, XH

AU - Zhao, SP

AU - Tian, YQ

AU - Betz, CS

PY - 2001/9/1

Y1 - 2001/9/1

N2 - Objective: To investigate the effectiveness of microinvasive Nd:YAG laser therapy in human glottic Tis and TI carcinomas, as well as its effect on the cellular immune function of the tumor-bearing hosts. Study Design: We treated 34 patients with microinvasive Nd:YAG laser therapy and evaluated its effect on the cellular immune function of the host. Methods: Thirty-four patients with glottic Tis or T1 squamous cell carcinoma were treated with fiberoptic laryngoscopic Nd: YAG laser surgery. Both before and after therapy, serum levels of soluble interleukin-2 receptor (SIL-2R) and interleukin-2 (IL-2), as well as natural killer (NK) cell activity, were determined by means of double-antibody sandwich technique, tritiated thymidine-deoxyribonucleoside incorporation, and iodine 125-uridine-deoxyribonucleoside release technique, respectively. Results. All 34 patients tolerated the procedure well. A 3- to 7-year follow-up in a subgroup of 27 patients resulted in an estimated cure rate of 85.2% (23 of 27 patients). In all 27 patients with a regular follow-up, a subjective improvement of phonation was noted after therapy to various degrees. In 74% (20 of 27 patients), voice and speech subjectively recovered to almost normal levels. The post-therapy serum levels of SIL-2R were significantly declined (P <.001), whereas those of IL-2 and the NK activity were significantly elevated (P <.001) as compared with those detected before therapy. Conclusions. Therapy with fiberoptic laryngoscopic Nd:YAG laser surgery is simple, safe, effective and only minimally invasive for patients with glottic Tis or T1 carcinoma. At the same time, it has an immunoenhancing effect on its host.

AB - Objective: To investigate the effectiveness of microinvasive Nd:YAG laser therapy in human glottic Tis and TI carcinomas, as well as its effect on the cellular immune function of the tumor-bearing hosts. Study Design: We treated 34 patients with microinvasive Nd:YAG laser therapy and evaluated its effect on the cellular immune function of the host. Methods: Thirty-four patients with glottic Tis or T1 squamous cell carcinoma were treated with fiberoptic laryngoscopic Nd: YAG laser surgery. Both before and after therapy, serum levels of soluble interleukin-2 receptor (SIL-2R) and interleukin-2 (IL-2), as well as natural killer (NK) cell activity, were determined by means of double-antibody sandwich technique, tritiated thymidine-deoxyribonucleoside incorporation, and iodine 125-uridine-deoxyribonucleoside release technique, respectively. Results. All 34 patients tolerated the procedure well. A 3- to 7-year follow-up in a subgroup of 27 patients resulted in an estimated cure rate of 85.2% (23 of 27 patients). In all 27 patients with a regular follow-up, a subjective improvement of phonation was noted after therapy to various degrees. In 74% (20 of 27 patients), voice and speech subjectively recovered to almost normal levels. The post-therapy serum levels of SIL-2R were significantly declined (P <.001), whereas those of IL-2 and the NK activity were significantly elevated (P <.001) as compared with those detected before therapy. Conclusions. Therapy with fiberoptic laryngoscopic Nd:YAG laser surgery is simple, safe, effective and only minimally invasive for patients with glottic Tis or T1 carcinoma. At the same time, it has an immunoenhancing effect on its host.

KW - fiberoptic laryngoscope

KW - laryngeal carcinoma

KW - microinvasive therapy

KW - Nd : YAG laser

KW - quality of voice

KW - soluble interleukin-2 receptor

KW - interleukin-2

KW - natural killer cell

U2 - 10.1097/00005537-200109000-00017

DO - 10.1097/00005537-200109000-00017

M3 - SCORING: Journal article

VL - 111

SP - 1585

EP - 1588

JO - LARYNGOSCOPE

JF - LARYNGOSCOPE

SN - 0023-852X

IS - 9

ER -